{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:15:09Z","timestamp":1780118109544,"version":"3.54.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>HIV pre-exposure prophylaxis (PrEP) is effective in preventing HIV, but some seroconversions occur due to poor adherence or PrEP discontinuation. Our objective was to estimate the incidence of PrEP discontinuation and describe the reasons and factors associated with discontinuations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort was conducted in three French hospitals between January 2016 and June 2022. PrEP users who attended at least twice within 6\u2005months during study period were included and followed up until December 2022. The incidence rate of PrEP discontinuation was estimated by censoring lost to follow up individuals. Factors associated with PrEP discontinuations were identified using a multivariate Cox model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 2785 PrEP users were included, with 94% men and 5% transgender people. Median age was 35\u2005years. By December 2022, 653 users had stopped PrEP (24%). The incidence rate was 10.8 PrEP discontinuations for 100 person-years (PY). The main causes of discontinuation were being in a stable relationship (32%), and not judging the treatment useful anymore (12%). Individuals who discontinued PrEP were younger [&amp;lt;29, HR\u200a=\u200a1.45 (1.17\u20131.80)], and more likely to be women [HR\u200a=\u200a2.44 (1.50\u20133.96)] or sex workers [HR\u200a=\u200a1.53 (0.96\u20132.44)]. They were more likely to report PrEP side effects [HR\u200a=\u200a2.25 (1.83\u20132.77)] or \u22652 sexually transmitted infections [HR\u200a=\u200a1.87 (1.53\u20132.27)] during the last year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The incidence of PrEP discontinuations was quite low compared to rates observed in other cohorts. Users who stopped PrEP were sometimes still exposed to HIV, emphasizing the need for targeted interventions to prepare and support PrEP discontinuations and limit seroconversion risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae133","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:00:55Z","timestamp":1715958055000},"page":"1555-1563","source":"Crossref","is-referenced-by-count":9,"title":["Incidence and factors associated with PrEP discontinuation in France"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3631-1828","authenticated-orcid":false,"given":"Nina","family":"Garofoli","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Sexual Health Clinic, Assistance Publique\u2014Hopitaux de Paris Nord, Bichat-Claude Bernard Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6447-0480","authenticated-orcid":false,"given":"Martin","family":"Siguier","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Assistance Publique\u2014Hopitaux de Paris, Tenon Hospital , Paris , France"},{"name":"Department of Infectious Diseases, Universit\u00e9 Sorbonne Paris Nord , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-5442","authenticated-orcid":false,"given":"Olivier","family":"Robineau","sequence":"additional","affiliation":[{"name":"Hospital Center of Tourcoing, Universitary Service of Infectious Diseases and Travel Medicine , Tourcoing , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Valette","sequence":"additional","affiliation":[{"name":"Hospital Center of Tourcoing, Universitary Service of Infectious Diseases and Travel Medicine , Tourcoing , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Phung","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Sexual Health Clinic, Assistance Publique\u2014Hopitaux de Paris Nord, Bichat-Claude Bernard Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Bachelard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Sexual Health Clinic, Assistance Publique\u2014Hopitaux de Paris Nord, Bichat-Claude Bernard Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rioux","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Sexual Health Clinic, Assistance Publique\u2014Hopitaux de Paris Nord, Bichat-Claude Bernard Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Le Gac","sequence":"additional","affiliation":[{"name":"Department of Research (Coordinator), COREVIH Ile-de-France Nord , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Digumber","sequence":"additional","affiliation":[{"name":"Department of Research (Coordinator), COREVIH Ile-de-France Nord , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pialoux","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Assistance Publique\u2014Hopitaux de Paris, Tenon Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Sexual Health Clinic, Assistance Publique\u2014Hopitaux de Paris Nord, Bichat-Claude Bernard Hospital , Paris , France"},{"name":"Department of Research (Coordinator), COREVIH Ile-de-France Nord , Paris , France"},{"name":"Inserm UMR1137, Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, IAME , Paris, F-75018 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Champenois","sequence":"additional","affiliation":[{"name":"Inserm UMR1137, Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, IAME , Paris, F-75018 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"2024070109570698700_dkae133-B1","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S2352-3018(18)30215-7","article-title":"Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study","volume":"5","author":"Grulich","year":"2018","journal-title":"Lancet HIV"},{"key":"2024070109570698700_dkae133-B2","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"2024070109570698700_dkae133-B3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV-1 prevention among heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"2024070109570698700_dkae133-B4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"2024070109570698700_dkae133-B5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"2024070109570698700_dkae133-B6","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1001\/jama.2019.2591","article-title":"Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US preventive services task force","volume":"321","author":"Chou","year":"2019","journal-title":"JAMA"},{"key":"2024070109570698700_dkae133-B7"},{"key":"2024070109570698700_dkae133-B8","doi-asserted-by":"crossref","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"key":"2024070109570698700_dkae133-B9","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2352-3018(22)00133-3","article-title":"Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study","volume":"9","author":"Molina","year":"2022","journal-title":"Lancet HIV"},{"key":"2024070109570698700_dkae133-B10","doi-asserted-by":"crossref","first-page":"e028768","DOI":"10.1136\/bmjopen-2018-028768","article-title":"Cohort profile: l\u2019Actuel pre-exposure prophylaxis (PrEP) cohort study in Montreal, Canada","volume":"9","author":"Greenwald","year":"2019","journal-title":"BMJ Open"},{"key":"2024070109570698700_dkae133-B11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/QAI.0000000000002506","article-title":"Patterns of PrEP retention among HIV pre-exposure prophylaxis users in Baltimore City, Maryland","volume":"85","author":"Wu","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024070109570698700_dkae133-B12","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","article-title":"Discontinuation, suboptimal adherence, and re-initiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2022","journal-title":"Lancet HIV"},{"key":"2024070109570698700_dkae133-B13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"2024070109570698700_dkae133-B14","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"key":"2024070109570698700_dkae133-B15"},{"key":"2024070109570698700_dkae133-B16","doi-asserted-by":"crossref","first-page":"e23688","DOI":"10.1371\/journal.pone.0023688","article-title":"Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS ONE"},{"key":"2024070109570698700_dkae133-B17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"HIV pre-exposure prophylaxis integrated with municipal and community based sexual health services","volume":"176","author":"Liu","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2024070109570698700_dkae133-B18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/QAI.0000000000002952","article-title":"Reasons for PrEP discontinuation following navigation at sexual health clinics: interactions among systemic barriers, behavioral relevance, and medication concerns","volume":"90","author":"Unger","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024070109570698700_dkae133-B19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/QAI.0000000000000362","article-title":"Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP","volume":"67","author":"Corneli","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024070109570698700_dkae133-B20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAI.0000000000001129","article-title":"Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation","volume":"73","author":"Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024070109570698700_dkae133-B21","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.2105\/AJPH.2015.302816","article-title":"How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: a call to destigmatize \u201cTruvada Whores\u201d","volume":"105","author":"Calabrese","year":"2015","journal-title":"Am J Public Health"},{"key":"2024070109570698700_dkae133-B22","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/QAI.0000000000002054","article-title":"Predictors of disengagement in care for individuals receiving pre-exposure prophylaxis (PrEP)","volume":"81","author":"Zucker","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024070109570698700_dkae133-B23","doi-asserted-by":"crossref","first-page":"e26056","DOI":"10.1002\/jia2.26056","article-title":"Discontinuation of government subsidized HIV pre-exposure prophylaxis in Australia: a whole-of-population analysis of dispensing records","volume":"26","author":"Medland","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"2024070109570698700_dkae133-B24","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/QAD.0000000000002970","article-title":"Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia","volume":"35","author":"Jin","year":"2021","journal-title":"AIDS"},{"key":"2024070109570698700_dkae133-B25","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1093\/jac\/dkab263","article-title":"PrEP monitoring and HIV incidence after PrEP initiation in France: 2016\u201318 nationwide cohort study","volume":"76","author":"Tassi","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024070109570698700_dkae133-B26","doi-asserted-by":"crossref","first-page":"e25953","DOI":"10.1002\/jia2.25953","article-title":"PrEP user profiles, dynamics of PrEP use and follow-up: a cohort analysis at a Belgian HIV centre (2017\u20132020)","volume":"25","author":"Rotsaert","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2024070109570698700_dkae133-B27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1071\/SH21207","article-title":"Utilisation of pre-exposure prophylaxis (PrEP) for HIV prevention in the Australian general practice setting: a longitudinal observational study","volume":"19","author":"Chidwick","year":"2022","journal-title":"Sex Health"},{"key":"2024070109570698700_dkae133-B28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/cid\/ciz894","article-title":"Pre-exposure prophylaxis uptake and discontinuation among young black men who have sex with men in Atlanta, Georgia: a prospective cohort study","volume":"71","author":"Serota","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024070109570698700_dkae133-B29","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s11121-022-01397-x","article-title":"Texting lost-to-follow-up PrEP patients from a San Francisco sexual health clinic","volume":"23","author":"Johnson","year":"2022","journal-title":"Prev Sci"},{"key":"2024070109570698700_dkae133-B30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/apc.2022.0004","article-title":"Lost2PrEP: understanding reasons for pre-exposure prophylaxis and sexual health care disengagement among men who have sex with men attending a sexual health clinic at a large urban academic medical center in New York City","volume":"36","author":"Rowe","year":"2022","journal-title":"AIDS Patient Care STDs"},{"key":"2024070109570698700_dkae133-B31","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/QAI.0000000000002625","article-title":"\u201cI just decided to stop\u201d: understanding PrEP discontinuation among individuals initiating PrEP in HIV care centers in Kenya","volume":"87","author":"Ongolly","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024070109570698700_dkae133-B32","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s10461-018-2102-9","article-title":"Barriers and facilitators to oral PrEP use among transgender women in New York City","volume":"22","author":"Rael","year":"2018","journal-title":"AIDS Behav"},{"key":"2024070109570698700_dkae133-B33","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1007\/s10461-015-1182-z","article-title":"Correlates of PrEP indication in a multi-site cohort of young HIV-uninfected transgender women","volume":"20","author":"Kuhns","year":"2016","journal-title":"AIDS Behav"},{"key":"2024070109570698700_dkae133-B34","doi-asserted-by":"crossref","first-page":"102733","DOI":"10.1016\/j.bjid.2022.102733","article-title":"Travestis, transgender women and young MSM are at high risk for PrEP early loss to follow-up in Rio de Janeiro, Brazil","volume":"27","author":"Echeverr\u00eda-Guevara","year":"2023","journal-title":"Braz J Infect Dis"},{"key":"2024070109570698700_dkae133-B35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/sextrans-2020-054618","article-title":"Pre-exposure HIV prophylaxis (PrEP) among transgender women: 3 years of follow-up in a university hospital in Paris","volume":"97","author":"Isernia","year":"2021","journal-title":"Sex Transm Infect"},{"key":"2024070109570698700_dkae133-B36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/hiv.13458","article-title":"PrEP for women in Europe: a systematic literature review","volume":"24","author":"Fitzgerald","year":"2023","journal-title":"HIV Med"},{"key":"2024070109570698700_dkae133-B37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/sextrans-2020-054457","article-title":"Risk perception, safer sex practices and PrEP enthusiasm: barriers and facilitators to oral HIV pre-exposure prophylaxis in Black African and Black Caribbean women in the UK","volume":"96","author":"Nakasone","year":"2020","journal-title":"Sex Transm Infect"},{"key":"2024070109570698700_dkae133-B38","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(23)00080-2","article-title":"Barriers and facilitators to HIV pre-exposure prophylaxis for cisgender and transgender women in the UK","volume":"10","author":"Whelan","year":"2023","journal-title":"Lancet HIV"},{"key":"2024070109570698700_dkae133-B39","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"2024070109570698700_dkae133-B40","doi-asserted-by":"crossref","first-page":"e10694","DOI":"10.2196\/10694","article-title":"A mobile-based app (MyChoices) to increase uptake of HIV testing and pre-exposure prophylaxis by young men who have sex with men: protocol for a pilot randomized controlled trial","volume":"8","author":"Biello","year":"2019","journal-title":"JMIR Res Protoc"},{"key":"2024070109570698700_dkae133-B41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1071\/SH18084","article-title":"Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care","volume":"15","author":"Tung","year":"2018","journal-title":"Sex Health"},{"key":"2024070109570698700_dkae133-B42","doi-asserted-by":"crossref","first-page":"e13982","DOI":"10.2196\/13982","article-title":"An electronic pre-exposure prophylaxis initiation and maintenance home care system for nonurban young men who have sex with men: protocol for a randomized controlled trial","volume":"8","author":"Siegler","year":"2019","journal-title":"JMIR Res Protoc"},{"key":"2024070109570698700_dkae133-B43","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2024070109570698700_dkae133-B44","year":"2021"},{"key":"2024070109570698700_dkae133-B45"},{"key":"2024070109570698700_dkae133-B46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fpubh.2020.00231","article-title":"Socioeconomic status and access to healthcare: interrelated drivers for healthy aging","volume":"8","author":"McMaughan","year":"2020","journal-title":"Front Public Health"},{"key":"2024070109570698700_dkae133-B47"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/7\/1555\/58375107\/dkae133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/7\/1555\/58375107\/dkae133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:57:58Z","timestamp":1719827878000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/7\/1555\/7675996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,5,17]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae133","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,5,17]]}}}